Neisseria meningitidis Group A IgG1 and IgG2 Subclass Immune Response in African Children Aged 12–23 Months Following Meningococcal Vaccination

Background. A group A meningococcal conjugate vaccine, PsA-TT, was licensed in 2010 and was previously studied in a phase 2 clinical trial to evaluate its safety and immunogenicity in African children 12–23 months of age. Methods. Subjects received either PsA-TT; meningococcal group A, C, W, Y polys...

Descripción completa

Detalles Bibliográficos
Autores principales: Holme, Daniel, Findlow, Helen, Sow, Samba O., Idoko, Olubukola T., Preziosi, Marie-Pierre, Carlone, George, Plikaytis, Brian D., Borrow, Ray
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2015
Materias:
The Meningitis Vaccine Project: The Development, Licensure, Introduction, and Impact of a New Group a Meningococcal Conjugate Vaccine for Africa
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4639486/
https://www.ncbi.nlm.nih.gov/pubmed/26553689
http://dx.doi.org/10.1093/cid/civ505

Ejemplares similares

Ejemplares similares